Revive Therapeutics (CSE: RVV) provided on Tuesday updates regarding the phase 3 clinical trial for oral drug bucillamine as a treatment for COVID-19. The firm has said it is “in the final stages” of the study and is preparing the regulatory application packages.
The trial has so far administered the drug to 701 subjects. It is also starting the trial enrollment in Turkey as part of its expanding and diversifying its clinical trial. The firm is working with Turkish hospital group MLP Care and Istinye University.
“We are now in the final stages in our Phase 3 study and we are focused on completing enrollment, preparing the regulatory packages for the FDA and international health authorities, and negotiating manufacturing and marketing agreements with pharmaceutical companies for commercialization,” said CEO Michael Frank.
The biotech firm is targeting to complete the trial by Q1 2022 and initiate its regulatory applications with the US Food and Drug Administration and other regional counterparts for approval.
Revive Therapeutics last traded at $0.28 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a former client of Canacom Group, the parent company of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.